To evaluate the potential of radioiodine labelled hypericin as a malignant glioma imaging agent, U-251 MG, U-373 MG, C6 glioma and fibroblast were treated with a I-123 labelled hypericin derivative and C6 glioma transplanted nude mouse were injected with a I-124 labelled hypericin derivative for a micro PET imaging. 2-Iodohypericin was prepared as a reference compound. In this paper, we describe the syntheses of 2-iodohypericin and 2-[ 
Introduction
Hypericin (1), a natural polycyclic aromatic dianthraquinone, has mostly been found in plants of the Hypericum genus (St. John's wort). St. John's wort has been considered as a medicinal herb and used in the treatment of a depression as a folk remedies.
1 Recent studies have found several interesting biological effects of 1 for its antiretroviral activity against several types of virus including human immunodeficiency virus (HIV). Clinical trials have been carried out using 1 with HIV-infected patients and positive results have been observed.
2-5 1 has been known to have a photodynamic therapeutic effect on some cancer types and its photosensitizing effect for photodynamic therapy (PDT) has been intensively explored. [6] [7] [8] [9] [10] One of the interesting investigations concerning 1 is an inhibitory effect on malignant glioma showing an elevated protein kinase C (PKC) activity, 11 and moreover its enhanced PKC activity strongly correlates with the growth rates of malignant gliomas. 12 One of the major concerns of this study is to evaluate the possibility of 1 as a malignant glioma imaging agent for PET (Positron Emission Tomography) or SPECT (Single Photon Emission Computed Tomography). PKC is a multi functional and ubiquitous enzyme system related with signal transduction pathways. 13 Recent interests have focused on a PKC expression level in malignant glioma cells because malignant glioma cells show an elevated PKC activity when compared to normal cells. 12 Other works have shown that PKC activities correlate with the proliferation rate of glioma and increased PKC activities thus reflect the malignancy of tumor cells.
14
Other works have demonstrated that manipulations of the PKC system can alter the growth rates of human malignant glioma cell lines in vitro and 1 has been demonstrated to have an inhibitory effect on PKC activity. 15, 16 Taken together the previous studied results, radioiodine labelled hypericin could possibly be used as a malignant glioma imaging agent. In this study, 2-iodohypericin (2) 
Results and Discussion
Hypericin (1) was synthesized as a precursor for a radio iodination and resulted in a relatively good yield of 65%. The irradiation of protohypericin in bright sunlight did not provide a sufficient energy for a photocyclization to produce hypericin while an irradiation with a 200 watt glow lamp for 24 hours produced an acceptable conversion yield of 91%. The reference compound, 2, was prepared by the reaction of hypericin and sodium iodide in the presence of peracetic acid. Although we did not separate the multi-iodinated hypericin, di-iodinated hypericin was found during the LC/ MS analysis as well as 2. [ CA group showed a higher uptake value when compared to those of the NCA group for C6, U-251 MG and U-373 MG. But, the NCA group showed a higher uptake value for fibroblast cell line. Although these results match the PDT related works concerning an enhanced tumor accumulation after an administration of relatively large amounts of hypericin (5 mg/kg) well, the exact mechanism and the role of the carrier hypericin in the over cellular uptake process remains unexplained. 22 C should be considered and evaluated.
Experimental Section
Chemistry and Radiochemistry. Hypericin (1) and iodinated hypericin were prepared and purified with silica and Sephadex LH-20 column chromatography by previously published methods with some modifications.
17,19,20
A similar method to a non-radioactive iodinated hypericin preparation was applied for the preparation of the radioiodinated hypericin. 17 The labeling reaction was monitored by radio-TLC and the labeling yield of [
123

I]2 was 60-65%. Purification of [
123 I]2 was performed on a semi-preparative high performance liquid chromatography (HPLC) system consisting of the following components: a Rheodyne 7010 injector equipped with a 2 mL sample loop, a Young-Lin M930 HPLC pump (Young-Lin, Korea) and a Young-Lin M720 UV detector (wavelength: 590 nm) in series with a Raytest GABI radioactivity detector (Raytest, Germany). A Waters X-terra radial R Prep RP18 column (300 × 7.8 mm, 10 mm) (Waters Corporation, Milford, USA) was eluted isocratically with a mixture of 50 mM aqueous ammonium acetate and absolute ethanol 30/70 (v/v) at a flow rate of 2 mL/min. [ I]2 in a C6 glioma bearing nude mouse. [ min. The product fraction (6 mL) was concentrated with a nitrogen stream to about 0.5 mL prior to use.
Binding Studies. The cell culture: Two human glioblastoma cell lines, U-251 MG and U-373 MG and one rat glioblastoma cell line, C6 were utilized in this study. Fibroblast from human skin was used instead of a low-passage malignant glioma cell. Cells were grown in Dulbecco's Modified Essential Medium (DMEM, Gibco BRL Products, Gaithersburg, MD) with 1.5 g/L sodium bicarbonate supplemented with 10% fetal bovine serum (FBS) and 100 mg/mL of penicillin-streptomycin (Gibco). Cells were maintained as monolayers in a humidified 5% CO 2 atmosphere, normally in T-75 flasks (Falcon, Becton Dickinson, Lincoln Park, NJ). The cells were trypsinated in the T-75 flasks at a 80-90% confluence using 0.05% trypsin/0.02% EDTA and were then suspended in DMEM with 10% FBS to the desired density, normally 1.2 × 10 6 cells/mL. Cell growth status and viability was monitored by an inverted phase contrast microscopy. Trypan blue exclusion was also used to assess their viability.
2-[
123 I]iodohypericin uptake: The four cell lines were seeded at 5 × 10 5 in 6 well plates at 3 mL per well and incubated at 37 o C in 5% carbon dioxide for 18 h for an adherence and growth. To each well in triplicate 100 µL of [ Tumor Model. Balb/C nude mice (7 weeks, 22 g) were used to prepare a tumor-bearing model. Mice were kept in cages with standardized conditions of light, asepsis and free access to water and food. Approximately 1 × 10 6 C6 glioma cells were inoculated subcutaneously on the back of the mice. Experiments were performed 7-14 days after an inoculation when a tumor diameter of about 0.7-1.0 cm was observed. All aspects of the animal experiment and husbandry were carried out in compliance with National regulations.
PET Studies. After 30 min of intravenous injection of [ 124 I]2 (3 MBq/200 µL), mice were sacrificed with a lethal dose of diethyl ether. Using a dedicated PET scanner (ECAT EXACT HR+ scanner, SIEMENS/CTIMI, Knoxville, Tenn), an acquisition was performed in a 2-dimensional mode. Using a germanium-68 source, transmission images were obtained for 5 min to correct photon attenuation. After the transmission scan, emission images were obtained for 15 min, and the acquisition data were reconstructed using an iterative reconstruction and segmented attenuation. The total acquisition time was 20 min.
Conclusion
In conclusion, the limited structural changes of hypericin showed a negligible effect on a glioma uptake in vivo and in vitro. This phenomenon has also been proved in other applications of hypericin derivatives in a biodistribution study 18 
